Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 13, 2026, 3:50 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 65 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Active Aspirin Clear all
Completed Not applicable Interventional Results available

The ARIES HeartMate 3 Pump IDE Study

NCT04069156
View directory record Official record
Conditions
Heart Failure
Interventions
LVAD Implant, Aspirin 100mg, Placebo oral tablet
Device · Drug
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
628 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
41
States / cities
Little Rock, Arkansas • La Jolla, California • Palo Alto, California + 31 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2025 · Synced Sep 13, 2026, 3:50 AM EDT
Terminated Phase 3 Interventional

Chemoprevention of Colorectal Adenomas

NCT00486512
View directory record Official record
Conditions
Adenomatous Polyps
Interventions
0.5 mg calcitriol (1a -25-dihydroxycholecalciferol), 75 mg acetylsalicylic acid (ASA) + 1250 mg calcium carbonate (CaCO3), placebo to 0.5 mg calcitriol (1a -25-dihydroxycholecalciferol), placebo to 75 mg acetylsalicylic acid (ASA) + 1250 mg calcium carbonate (CaCO3), Colonoscopy
Drug · Procedure
Lead sponsor
Colotech A/S
Industry
Eligibility
40 Years to 75 Years
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
24
States / cities
Huntsville, Alabama • San Diego, California • Clearwater, Florida + 20 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2020 · Synced Sep 13, 2026, 3:50 AM EDT
Completed No phase listed Observational

Patients Undergoing Percutaneous Coronary Intervention (PCI) Through Optimal Platelet Inhibition

NCT01582217
View directory record Official record
Conditions
Percutaneous Coronary Intervention, Dual Antiplatelet Therapy, Aspirin, Clopidogrel
Interventions
Not listed
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
318 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 22, 2015 · Synced Sep 13, 2026, 3:50 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Aspirin and Thienopyridine Resistance in Peripheral Arterial Disease

NCT03174990
View directory record Official record
Conditions
Peripheral Arterial Disease, Clopidogrel, Poor Metabolism of
Interventions
Not listed
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
195 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jun 4, 2017 · Synced Sep 13, 2026, 3:50 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Cardiovascular Disease (CVD) Risk and Prevention in Early Glucose Intolerance

NCT00122447
View directory record Official record
Conditions
Impaired Glucose Tolerance, Prediabetic State
Interventions
Aspirin, Alpha lipoic acid, Olmesartan, Placebo
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 75 Years
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2011
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 4, 2013 · Synced Sep 13, 2026, 3:50 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

The Accuracy Of A Novel Platelet Activity Assay In Humans On Antiplatelet Agents: Pharmacodynamics And Comparison With Light Transmission Aggregometry

NCT04822363
View directory record Official record
Conditions
Platelet Activation Testing Before/After Anti-platelet Therapy, Healthy
Interventions
Aspirin, Clopidogrel
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
112 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Sep 13, 2026, 3:50 AM EDT
Not listed Phase 1Phase 2 Interventional Accepts healthy volunteers

Reversal of Aspirin Antiplatelet Therapy With Cold Stored Platelets

NCT05111028
View directory record Official record
Conditions
Reversal of Platelet Aggregation Inhibitors
Interventions
Autologous Room Temperature stored Platelet transfusion, Autologous Cold Stored Platelet transfusion
Biological
Lead sponsor
Bloodworks
Other
Eligibility
18 Years to 59 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 7, 2021 · Synced Sep 13, 2026, 3:50 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of the Nottingham Augmented Reality (AR) App for Arthritis Hand Joint Pain

NCT05634291
View directory record Official record
Conditions
Chronic Pain, Arthritis Hand, Opioid Use
Interventions
Standard of care, Nottingham AR smartphone app with active intervention
Other · Device
Lead sponsor
VRx Medical Inc
Industry
Eligibility
21 Years to 80 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jul 24, 2023 · Synced Sep 13, 2026, 3:50 AM EDT
Completed Phase 2Phase 3 Interventional

Effectiveness of a Training Program in Improving Coping Skills in People With Arthritis Pain

NCT00636454
View directory record Official record
Conditions
Osteoarthritis
Interventions
Coping skills training (CST) for chronic pain, Usual care
Behavioral · Other
Lead sponsor
Stony Brook University
Other
Eligibility
21 Years and older
Enrollment
257 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
3
States / cities
Setauket, New York • Smithtown and Port Jefferson, New York • Danville, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 26, 2013 · Synced Sep 13, 2026, 3:50 AM EDT
Terminated Phase 3 Interventional Results available

Rivaroxaban Versus Aspirin in Secondary Prevention of Stroke and Prevention of Systemic Embolism in Patients With Recent Embolic Stroke of Undetermined Source (ESUS)

NCT02313909
View directory record Official record
Conditions
Stroke
Interventions
Rivaroxaban (Xarelto, BAY59-7939), Acetylsalicylic acid (Aspirin, BAY1019036), Rivaroxaban-Placebo, Aspirin-Placebo
Drug · Other
Lead sponsor
Bayer
Industry
Eligibility
50 Years and older
Enrollment
7,213 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
38
States / cities
Tucson, Arizona • Long Beach, California • Stanford, California + 32 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2019 · Synced Sep 13, 2026, 3:50 AM EDT
Completed Phase 3 Interventional Results available

Pharmacodynamic Evaluation of PL2200 Versus Enteric-Coated and Immediate Release Aspirin in Diabetic Patients

NCT01515657
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
PL2200 Aspirin Capsules, Immediate-Release Aspirin Tablets, Enteric-coated aspirin caplets
Drug
Lead sponsor
PLx Pharma
Industry
Eligibility
21 Years to 79 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 13, 2016 · Synced Sep 13, 2026, 3:50 AM EDT
Completed Phase 4 Interventional Results available

Clinical Effects of Eptifibatide Administration in High Risk Patients Presenting With Non-ST Segment Elevation Acute Coronary Syndrome (NSTE-ACS) Requiring Urgent Coronary Artery Bypass Graft Surgery in Short- and Long-Term Follow-up

NCT01863134
View directory record Official record
Conditions
Non ST Elevation Myocardial Infarction
Interventions
Eptifibatide, Placebo
Drug
Lead sponsor
Medical University of Silesia
Other
Eligibility
21 Years to 75 Years
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 30, 2013 · Synced Sep 13, 2026, 3:50 AM EDT
Completed Phase 3 Interventional

Precision Medicine Approach for Early Dementia & Mild Cognitive Impairment

NCT05894954
View directory record Official record
Conditions
Mild Cognitive Impairment, Dementia, Mild
Interventions
Precision Medicine Approach, Hormones and Medications tailored to lab tests, combined with devices that support stress management and brain exercises, Standard-of-Care, Lifestyle including diet, exercise, stress management
Dietary Supplement · Combination Product · Behavioral
Lead sponsor
Alzheimer's Prevention and Reversal Project, Inc.
Other
Eligibility
45 Years to 76 Years
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
6
States / cities
Folsom, California • San Rafael, California • Walnut Creek, California + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Sep 13, 2026, 3:50 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

The Effect of a Probiotic Strain on Aspirin-induced GI Damage

NCT03910322
View directory record Official record
Conditions
Reduction of Small Intestinal Ulceration Risk
Interventions
Bif195, Placebo
Dietary Supplement
Lead sponsor
Chr Hansen
Industry
Eligibility
40 Years to 60 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 25, 2020 · Synced Sep 13, 2026, 3:50 AM EDT
Completed Phase 3 Interventional Results available

Dabigatran Etexilate for Secondary Stroke Prevention in Patients With Embolic Stroke of Undetermined Source (RE-SPECT ESUS)

NCT02239120
View directory record Official record
Conditions
Stroke, Secondary Prevention
Interventions
optional ASA as comedication, placebo to ASA, placebo to optional ASA as comedication, placebo to dabigatran etexilate, ASA 100 mg, dabigatran etexilate
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 150 Years
Enrollment
5,390 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
110
States / cities
Phoenix, Arizona • Beverly Hills, California • El Cajon, California + 94 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2019 · Synced Sep 13, 2026, 3:50 AM EDT
Completed Phase 3 Interventional Results available

Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE I)

NCT00249795
View directory record Official record
Conditions
Atrial Fibrillation, Cardiovascular Disease
Interventions
Irbesartan, placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
9,016 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 14, 2010 · Synced Sep 13, 2026, 3:50 AM EDT
Completed Phase 3 Interventional Results available

Trial to See if Topical Pennsaid for Knee Pain Affects Coagulation Values in Patients Who Are Also Taking Anticoagulants

NCT01511939
View directory record Official record
Conditions
Osteoarthritis of the Knee, Coagulopathy
Interventions
Pennsaid
Drug
Lead sponsor
Nathan Wei, MD, FACP, FACR:
Other
Eligibility
55 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Frederick, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 25, 2014 · Synced Sep 13, 2026, 3:50 AM EDT
Terminated Phase 3 Interventional Results available

A Phase 3, Multicenter, Randomized, Double-blind,Active-controlled, Parallel-group Trial With an Open-labelExtension Phase to Evaluate the Efficacy and Safety of OralE5501 Versus Eltrombopag, in Adults With Chronic ImmuneThrombocytopenia (Idiopathic Thrombocytopenic Purpura)

NCT01433978
View directory record Official record
Conditions
Idiopathic Thrombocytopenic Purpura
Interventions
Eltrombopag, Avatrombopag, Standard of care
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 99 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Watertown, South Dakota
Source: ClinicalTrials.gov public record
Updated Feb 5, 2018 · Synced Sep 13, 2026, 3:50 AM EDT
Terminated Phase 3 Interventional Results available

AtRial Cardiopathy and Antithrombotic Drugs In Prevention After Cryptogenic Stroke

NCT03192215
View directory record Official record
Conditions
Stroke
Interventions
Apixaban, Aspirin
Drug
Lead sponsor
Columbia University
Other
Eligibility
45 Years and older
Enrollment
1,015 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
165
States / cities
Birmingham, Alabama • Mobile, Alabama • Chandler, Arizona + 111 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2025 · Synced Sep 13, 2026, 3:50 AM EDT
Completed Phase 3 Interventional Results available

Pharmacodynamic Evaluation of PL2200 Versus Enteric-Coated Aspirin in Diabetic Patients

NCT02008942
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
PL2200 Aspirin Capsules, Enteric-coated aspirin caplets
Drug
Lead sponsor
PLx Pharma
Industry
Eligibility
21 Years to 79 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
3
States / cities
Miami, Florida • Lenexa, Kansas • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 9, 2016 · Synced Sep 13, 2026, 3:50 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

PACT (Platelet Activity After Clopidogrel Termination)

NCT00619073
View directory record Official record
Conditions
Blood Platelets, Clopidogrel
Interventions
clopidogrel + aspirin, placebo, Aspirin
Drug
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
21 Years to 70 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 30, 2018 · Synced Sep 13, 2026, 3:50 AM EDT
Recruiting Phase 3 Interventional

Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia

NCT02735707
View directory record Official record
Conditions
Community-acquired Pneumonia, Influenza, COVID-19
Interventions
Ceftriaxone, Moxifloxacin or Levofloxacin, Piperacillin-tazobactam, Ceftaroline, Amoxicillin-clavulanate, Standard course macrolide, Extended course macrolide, No systemic corticosteroid, Fixed-duration Hydrocortisone, Shock-dependent hydrocortisone, Fixed-duration higher dose Hydrocortisone, No antiviral agent for influenza, Five-days oseltamivir, Ten-days oseltamivir, No antiviral agent for COVID-19, Lopinavir / Ritonavir, Hydroxychloroquine, Hydroxychloroquine + lopinavir/ritonavir, Ivermectin, No immune modulation for COVID-19, Interferon beta-1a, Anakinra, Tocilizumab, Sarilumab, Local standard venous thromboprophylaxis, Therapeutic dose anticoagulation, Conventional low dose thromboprophylaxis, Intermediate dose thromboprophylaxis, Continuation of therapeutic dose anticoagulation, No immunoglobulin, Convalescent plasma, Delayed administration of convalescent plasma, No vitamin C, Vitamin C, No antiplatelet, Aspirin, P2Y12 inhibitor, No simvastatin, Simvastatin, Eritoran, Apremilast, Clinician-preferred mechanical ventilation strategy, Protocolised mechanical ventilation strategy, No renin-angiotensin system inhibitor, Angiotensin converting enzyme inhibitor, Angiotensin Receptor Blockers, ARB + DMX-200, No cysteamine, Cysteamine, Fixed-duration dexamethasone, Baloxavir Marboxil, Five-days oseltamivir + baloxavir marboxil, Ten-days oseltamivir + baloxavir marboxil, No endothelial modulator, Imatinib, No Immune Modulator for Influenza, Baricitinib, Nirmatrelvir/ritonavir, Remdesivir, Nirmatrelvir/ritonavir + remdesivir
Drug · Other · Biological + 1 more
Lead sponsor
UMC Utrecht
Other
Eligibility
18 Years and older
Enrollment
20,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2028
U.S. locations
11
States / cities
Jacksonville, Florida • Augusta, Georgia • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2024 · Synced Sep 13, 2026, 3:50 AM EDT
Completed Phase 2 Interventional Results available

A Study to Compare the Safety of Rivaroxaban Versus Acetylsalicylic Acid in Addition to Either Clopidogrel or Ticagrelor Therapy in Participants With Acute Coronary Syndrome

NCT02293395
View directory record Official record
Conditions
Acute Coronary Syndrome
Interventions
Acetylsalicylic acid, Rivaroxaban, Clopidogrel, Ticagrelor
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
3,037 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
49
States / cities
Alexander City, Alabama • Banning, California • Sylmar, California + 46 more
Source: ClinicalTrials.gov public record
Updated Dec 25, 2017 · Synced Sep 13, 2026, 3:50 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

The Role of Cyclooxygenase Activity in the Endothelial Function of Hypertensive and Hypercholesterolemic Patients

NCT00001742
View directory record Official record
Conditions
Healthy, Hypercholesterolemia, Hypertension
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
Not listed
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1998 – 2001
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 13, 2026, 3:50 AM EDT